TransMedics Group (NASDAQ: TMDX) reported Q2 EPS of $0.92, $0.47 better than the analyst estimate of $0.45. Revenue for the quarter came in at $157.4 million versus the consensus estimate of $146.74 million.

GUIDANCE:

TransMedics Group sees FY2025 revenue of $585-605 million, versus the consensus of $582.1 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.